1. Medtech Insight
  2. >>Business
  3. >>Deals

Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models

Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.

The year 2014 was a heady one for medtech M&A, with bigger deals and more invested in them than ever before – $89.3 billion, according to Informa’s Strategic Transactions.

A lot of the 2014 M&A impetus was driven by pressures in the US to find a way around the high corporate tax rate. (See Also see "Biopharma In 2014: Early Access Gains Offset Taxation, Pricing Woes" - In Vivo, 21 January, 2015..) It turned out that the other US tax – the Patient Protection and Affordable Care Act’s 2.3% tax on medtech sales – was less of a problem, but it remained as vilified as ever by US market entrants as 2014 turned into 2015

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 
• By Natasha Barrow

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

Careology And Entia Partner To ‘Enhance’ Remote Monitoring For Patients With Cancer

 
• By Natasha Barrow

Careology and Entia are partnering to “alleviate the burden of routine patient assessments” on people with cancer. The two early-stage London-based health tech startups already provide services to UK National Health Service (NHS) patients.

More from Business

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By Elizabeth Orr

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.